Vor Biopharma (NYSE:VOR) Price Target Lowered to $15.00 at Barclays

Vor Biopharma (NYSE:VORGet Rating) had its target price cut by Barclays from $26.00 to $15.00 in a research report report published on Friday morning, The Fly reports. They currently have an overweight rating on the stock.

A number of other brokerages have also recently commented on VOR. Wedbush restated an initiates rating on shares of Vor Biopharma in a research note on Tuesday, July 26th. HC Wainwright dropped their price target on shares of Vor Biopharma from $26.00 to $20.00 and set a buy rating on the stock in a research note on Monday, August 15th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average price target of $22.00.

Vor Biopharma Stock Up 2.9 %

VOR opened at $4.30 on Friday. The stock has a market cap of $163.64 million, a price-to-earnings ratio of -1.86 and a beta of -0.11. The company’s 50-day moving average price is $4.36 and its two-hundred day moving average price is $4.72. Vor Biopharma has a twelve month low of $3.48 and a twelve month high of $18.35.

Institutional Trading of Vor Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the company. Paradigm Biocapital Advisors LP lifted its stake in Vor Biopharma by 42.1% in the 1st quarter. Paradigm Biocapital Advisors LP now owns 894,404 shares of the company’s stock worth $5,402,000 after purchasing an additional 265,062 shares in the last quarter. Citadel Advisors LLC increased its holdings in shares of Vor Biopharma by 37.8% in the 2nd quarter. Citadel Advisors LLC now owns 79,374 shares of the company’s stock worth $394,000 after buying an additional 21,765 shares during the last quarter. Bank of Montreal Can bought a new position in shares of Vor Biopharma in the 1st quarter worth $283,000. Goldman Sachs Group Inc. increased its holdings in shares of Vor Biopharma by 48.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 25,607 shares of the company’s stock worth $155,000 after buying an additional 8,370 shares during the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in shares of Vor Biopharma in the 3rd quarter worth $131,000. 81.87% of the stock is currently owned by hedge funds and other institutional investors.

About Vor Biopharma

(Get Rating)

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

See Also

The Fly logo

Analyst Recommendations for Vor Biopharma (NYSE:VOR)

Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.